FATE

NASDAQ open

Fate Therapeutics

0.95 USD
▼-0.06-6.22%
盘后 1.88 0.00%
2026-11-20
市值
$111.72M
市盈率
—
EPS
-1.03
股息率
—
52 周区间
0.95 – 3.23
成交量
2.28M
Beta
2.67
目标价
5.72
52W 低 0.9552W 高 3.23
价格走势

公司简介

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tum...